slide 4/210 = shows the disclosures....(Mary L. Disis on the list from above) and BMS is all over the place here and this was back on Sept 27, 2012!!! when this came out so could you imagine the backfire that Peregrine would be waging against them if no "coding discrepancies" in Fargo took place? I'd like to see one of these former/current BMS backers (KOL's..etc) to come out and declare: "Yes, PS is a biomarker on tumor cells and by targeting PS... a greater "optimal immune response" is the result!
slide 18/210 = BMS's version of the "optimal immune response" ... where the hell is PS in all these slides ?? oh where oh where is PS ??? lol
these 210 slides will keep me busy for a while.... so no more posts for tonight : ) and can you believe that BMS was trying to write the history books for immuno-oncology before all the facts are on the table! Lets go Federal Authorities.... follow all leads and break up this little generation long BMS party and we are all aware that its probably a political tight rope balance but examples must be set somewhere along the line. We have many medical professionals that need to be made aware of what the night nurses have known for way too long. ... .. So slide 18/210 can kiss my A$$.
A big puzzle pieces comes out of this corner back in Sept of 2012 that would have placed a big wrinkle in that slidedeck over at Bristol Myers Squibb...but this post is simply to show that its all about BIO-MARKERS and how the Biomarker Task Force has expanded since 2012
-------------------------------------------
Biomarkers Task Force 2014
The Biomarkers Task Force initiative was made possible by the:
Steering Committee FDA Liaison Working Group 1 - Immunologic Monitoring, Assay Standardization & Validation Working Group 2 - New Developments in Biomarker Assays & New Technologies Working Group 3 - Assessment of Immune Regulation & Modulation Systematically (High Throughput Approaches) Working Group 4 - Prediction of Clinical Outcome Based on Baseline Measures
Steering Committee Chair
Lisa H. Butterfield, PhD University of Pittsburgh Cancer Institute Co-Chairs
Mary L. Disis, MD University of Washington
Bernard A. Fox, PhD Earle A. Chiles Research Institute
Samir N. Khleif, MD Georgia Health Sciences
Francesco Marincola, MD Sidra Medical and Research Center FDA Liaison
Raj K. Puri, MD, PhD FDA, CBER Working Group 1 - Immunologic Monitoring, Assay Standardization & Validation Co-Chairs
Magdalena Thurin, PhD National Cancer Institute
Guiseppe V. Masucci, MD, PhD Karolinska University Hospital, Solna Members
John Alvarez, MD, PhD Janssen R&D
Alessandra Cesano, MD, PhD Cleave Biosciences
Kevin K. Dobbin, PhD University of Georgia
Rachael Hawtin, PhD Nodality
Sylvia Janetzki, MD Zellnet Consulting, Inc.
Ilan Kirsch, MD Adaptive Technologies
Raj K. Puri, MD, PhD FDA, CBER
Paul Robbins, PhD MedImmune
Senthamil R. Selvan, PhD BriaCell
Howard Z. Streicher, MD National Cancer Institute - Cancer Therapy Evaluation Program
Zhe Zhang, PhD Mayo Clinic Working Group 2 - New Developments in Biomarker Assays & New Technologies Chair
Jianda Yuan, MD Memorial Sloan Kettering Cancer Center Members
Raphael Clynes, MD, PhD Bristol-Myers Squibb
Periklis Foukas, MD, PhD CHUV
Bernard A. Fox, PhD Earle A. Chiles Research Institute
Alexandre Harari, PhD CHUV
Priti Hegde, PhD Genentech
Thomas O. Kleen, PhD Epiontis GmbH
Pia Kvistborg, PhD Netherlands Cancer Institute
Christina Maccalli, PhD Italian Network for Biotherapy of Tumors
Holden T. Maecker, PhD Stanford University Medical Center
Harlan Robins, PhD Adaptive Technologies
Wenru Song, MD, PhD AstraZeneca
Edward C. Stack, PhD PerkinElmer
Ena Wang, MD Sidra Medical and Research Center
Theresa L. Whiteside, PhD University of Pittsburgh Cancer Institute
Yingdong Zhao, PhD National Cancer Institute
Heinz Zwierzina, MD Medizinishe Universitat Innsbruck Working Group 3 - Assessment of Immune Regulation & Modulation Systematically (High Throughput Approaches) Chair
David F. Stroncek, MD National Institutes of Health Members
Michael Cannarile, PhD Roche Innovation Center Zurich
Madhav Dhodapkar, MD Yale University
Tim Greten, MD National Institutes of Health
David Kaufman, MD, PhD Merck
Peter P. Lee, MD City of Hope
Francesco Marincola, MD Sidra Medical and Research Center
Sergio Rutella, MD, PhD Sidra Medical and Research Center
Barbara Seliger, MD, PhD Institute of Medical Immunology, Martin Luther University of Halle-Wittenberg
Janet Siebert, MS CytoAnalytics
Giorgio Trinchieri, MD National Cancer Institute Working Group 4 - Prediction of Clinical Outcome Based on Baseline Measures Chair
Sacha Gnjatic, PhD Members
Vincenzo Bronte, MD Instituto Oncologico Veneto and Venetian Institute for Molecular Medicine
Laura Rosa Brunet, DSc Immodulon
Marcus Butler, MD Princess Margaret Cancer Centre
Mary L. Disis, MD University of Washington
Jerome Galon, MD INSERM
Leif G. Hakansson, MD, PhD Biotherapy Development Association
Brent A. Hanks, MD, PhD Duke University
Vaios Karanikas, PhD Roche Innovation Center Zurich
Samir N. Khleif, MD GRU Cancer Center
John M. Kirkwood, MD University of Pittsburgh
Lance Miller, PhD Wake Forest Baptist Medical Center
Dolores J. Schendel, PhD Medigene Immunotherapies GmbH
Big list of names to cross-reference and to pick just one for the time being (especially off the latest MSK/PPHM collaborations), would be Jianda Yuan and make the MSK connection to Dr. Jedd Wolchok & Taha Merghoub @ Memorial Sloan Kettering.
----------------------------------
Working Group 2 - New Developments in Biomarker Assays & New Technologies Chair
Jianda Yuan, MD Memorial Sloan Kettering Cancer Center
---------------------------------
Monoclonal Antibodies
Monoclonal antibodies are molecules, generated in the lab, that target specific antigens on tumors.
A phase Ib trial of GR-MD-02, a galectin inhibitor, plus ipilimumab in patients with metastatic melanoma (NCT02117362).
A phase Ib trial of bavituximab, an antibody that targets an immune-suppressing molecule in tumors, plus ipilimumab in patients with advanced melanoma (NCT01984255).
........... ........... ........
CRI researchers Jianda Yuan, M.D., Ph.D., Sacha Gnjatic, Ph.D., Jedd D. Wolchok, M.D., Ph.D., and others found that cancer patients ...
So we know for a fact that Dr. Jedd Wolchok and Taha Merghoub will be working with PS Targeting, and I'd say that Jianda Yuan (Laboratory Mananger Immune Monitoring... and Translational Tumor Immunologist) will certainly be working with PS Targeting as well.
The studies at MSK will be performed under the direction of Taha Merghoub, PhD, [ www.mskcc.org/research-areas/labs/members/taha-merghoub-01 ] Associate Attending Biologist, Melanoma and Immunotherapeutics Service, Ludwig Collaborative and the Swim Across America Laboratory, a part of the laboratory of Jedd D. Wolchok, MD, PhD [ http://www.mskcc.org/research-areas/labs/jedd-wolchok ], a leader in the field of cancer immunotherapy. Dr. Wolchok serves as the Chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation as well as an Associate Director of the Ludwig Center for Cancer Immunotherapy at MSK.
"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Wolchok.
As part of the collaboration, researchers at MSK will conduct research to further explore the combination of PS-targeting agents, including bavituximab, that block a primary immunosuppressive pathway thereby allowing anti-tumor immune responses with other immuno-stimulatory agents that enhance immune responses. Specifically, MSK researchers will examine the combination of bavituximab alongside models of checkpoint blockade that are unresponsive to inhibition or co-stimulation given the ability of bavituximab to reprogram myeloid derived suppressor cells (MDSC) and increase tumoricidal T-cells in tumors, a mechanism of action that is complementary to checkpoint blockade and T-cell activation.
"A key focus of the Wolchok Lab's research is studying novel immunotherapy combinations that work together to enable the immune system to recognize and destroy cancer. This collaboration will allow us to focus on the role and contribution of PS blockade therapy in determining which combination of the current and next generation of immune modulators is likely to increase the extent and amplitude of anti-tumor response. This important pre-clinical and translational work will potentially guide the design of the next generation of clinical studies with bavituximab," said Dr. Merghoub.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
